Abivax (AAVXF) Share-based Compensation (2024 - 2026)

Abivax has reported Share-based Compensation for 3 years, with the latest figure at $26.5 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 436.68% year-over-year to $26.5 million in Q1 2026; TTM through Mar 2026 was $41.2 billion, a 90.76% increase from a year earlier, with the FY2025 full-year figure at $41.2 billion, up 90.66% from the prior year.
• Share-based Compensation was $26.5 million for Q1 2026 at Abivax, down from $41.2 billion in the prior quarter.
• The five-year high for Share-based Compensation was $41.2 billion in Q4 2025, with the low at $4.8 million in Q3 2024.
• Average Share-based Compensation over 3 years is $7.0 billion, with a median of $7.2 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation dropped 21.11% in 2025, then jumped 436.68% in 2026.
• Over 3 years, Share-based Compensation stood at $21.6 billion in 2024, then soared by 90.69% to $41.2 billion in 2025, then slumped by 99.94% to $26.5 million in 2026.
• The last three Share-based Compensation figures came in at $26.5 million (Q1 2026), $41.2 billion (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.